EUCTR2005-003351-12-BE进行中（未招募）不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 2,715
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria: Double-Blind Phase
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- •1. Written informed consent obtained prior to the initiation of any study procedures;
- •2. Male or female subjects, =55 years of age at the time informed consent is obtained;
- •3. Chronic systolic heart failure (HF) of either ischemic or non ischemic etiology.
- •a. Duration: at least 4 weeks;
- •b. Left ventricular ejection fraction (LVEF): =30% by echocardiography, contrast ventriculography, magnetic resonance imaging or nuclear imaging, based on local clinical practice. The most recent measurement within 6 months prior to randomization must be used.
- •Left ventricular ejection fraction (LVEF) =35% in addition to QRS duration =130 msec. It is mandatory that subjects with LVEF 31-35% must also have QRS duration =130 msec to be eligible for this trial.
- •c. Functional Capacity: Currently NYHA II (in the investigator’s opinion);
- •d. Treatments (for ACE inhibitors, ARBs and ß-blockers, optimal target or maximal tolerated dose [See Appendix 1 of the protocol Optimal Target Doses of Angiotensin Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs) and ß- Blockers] unless contraindicated).
- •Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs);
- •ß-blocker;
- •Diuretic, if clinically indicated to reduce fluid retention;
- •4. Serum potassium (K+) level =5.0mmol/L within 24 hours prior to randomization.
- •5. Estimated glomerular filtration rate (eGFR) =30 ml/min/1.73m2 within 24 hours prior to randomization (See Appendix 2 of the protocol Calculation of Estimated Glomerular Filtration Rate (eGFR)).
- •6. Randomization must occur no later than 6 months from the date of admission to hospital for a cardiovascular reason (see definition of cardiovascular hospitalization below). If the subject is clinically stable, he or she may be randomized during admission for a cardiovascular reason.
- •In the absence of a recent admission to hospital for a cardiovascular reason, documentation of a plasma concentration of B type natriuretic peptide (BNP) of at least 250 pg/ml or amino terminal proB type natriuretic peptide (NT proBNP) of at least 500 pg/ml for males and 750 pg/ml for females, within 15 days of randomization.
- •Cardiovascular (CV) hospitalization is defined as hospitalization for:
- •Heart Failure (first or subsequent)
- •Acute myocardial infarction
- •Angina pectoris (unstable)
- •Cardiac arrhythmia (atrial fibrillation, atrial flutter, supraventricular arrhythmias, or ventricular arrhythmias)
- •Stroke/cerebral vascular accident (CVA)
- •Other CV reasons (eg, hypotension, peripheral vascular disease)
- •Hospitalization for an elective cardiovascular procedure does not qualify for entry into this trial unless the subject was hospitalized for implantation of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT).
- •7. If the subject is a female, the following should apply.
- •a. Have a negative serum pregnancy within 72 hours prior to the first dose of study drug, except if she previously had a total hysterectomy or is >65 years old;
- •b. Agree to use an adequate form of contraception (Abstinence will not be considered an acceptable form of contraception) if she is of child bearing potential.
- •8. Subjects previously treated with an aldosterone antagonist for >7 consecutive days will be allowed if they fulfill the following criteria:
- •a. No history of clinic
排除标准
- •Exclusion Criteria: Double-Blind Phase
- •Subjects presenting with any of the following will not be included in the trial:
- •1. Patients with severe chronic systolic heart failure, defined as patients who demonstrate symptoms usually at rest despite optimal medical therapy.
- •2. Patients with a myocardial infarction complicated by left ventricular systolic dysfunction and clinical heart failure within 30 days prior to randomization.
- •3. Patients with stroke within 30 days prior to randomization.
- •4. Patients who have had cardiac surgery within 30 days prior to randomization.
- •5. Patients who have had percutaneous coronary intervention (PCI) within 30 days prior to randomization.
- •6. Patients previously exposed to treatment with an aldosterone antagonist for >7 consecutive days, in whom the aldosterone antagonist has not been discontinued permanently for at least 3 months prior to randomization, or patients who have a history of clinically significant hyperkalemia or renal impairment during a previous exposure to an aldosterone antagonist.
- •7. Patients who require treatment with eplerenone, spironolactone or potassium canrenoate and either have prior NYHA class IV heart failure associated with a LVEF =0.35 (as in the RALES trial) [2] or heart failure or diabetes and a LVEF <0.40 after acute MI (as in EPHESUS trial).
- •8. Patients with uncontrolled hypertension, defined as having a systolic blood pressure >180 mmHg and/or a diastolic blood pressure >110 mmHg.
- •9. Patients with symptomatic hypotension or having a systolic blood pressure <85 mmHg.
- •10. Patients, who in the opinion of the investigator, require treatment with potassium sparing diuretics.
- •11. History of hypersensitivity to eplerenone or spironolactone.
- •12. Evidence of cardiogenic shock.
- •13. Patients in whom the primary cause of heart failure is surgically amenable valve disease, pericardial disease or an obstructive or restrictive cardiomyopathy.
- •14. Intra aortic balloon pump or other mechanical assist device.
- •15. Patients awaiting cardiac transplantation.
- •16. Serum potassium >5.0 mmol/L within 24 hours prior to randomization.
- •17. Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2 within 24 hours prior to randomization (See Appendix 2 of the protocol, Calculation of eGFR).
- •18. Concomitant use of potent cytochrome p450 3A4 (CYP3A4) inhibitors, such as but not limited to:
- •a Ketoconazole;
- •b Itraconazole;
- •c Nefazodone;
- •d Troleandomycin;
- •e Clarithromycin;
- •f Ritonavir;
- •g Nelfinavir.
- •19. Concomitant use of cytochrome p450 3A4 (CYP3A4) inducers, such as but not limited to:
- •a St. John’s Wort;
- •b Rifampin;
- •c Carbamazepine;
- •d Phenytoin;
- •e Phenobarbitol.
- •20. Hemoglobin <10g/dL.
- •21. Patients with preexisting significant hepatic disease (for example, known positive serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 times the upper limits of normal.
- •22. Patients status post gastric bypass surgery, partial gastrectomy or other surgery of the gastrointestinal tract that may interfere with the absorption of eplerenone.
- •23. Patients with preexisting serious conditions (eg, cancer, Acquired Immunodeficiency Syndrome (AIDS). Patients with a previous history of cancer will be eligible if in the opinion of the investigator life expectancy is anticipated to be greater than 5 years.
- •24. Patients unable to give written informed consent.
- •25. Patients with a progressively fatal disease (except congestive heart failure) and/or life expectancy less than 3
研究者
相似试验
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-PTaboratórios Pfizer, Lda2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-IEPfizer Limited2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AEUCTR2005-003351-12-CZPfizer Ltd2,715
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart FailureEfecto de eplerenona versus placebo sobre la mortalidad cardiovascular y la hospitalización por insuficiencia cardiaca en sujetos con insuficiencia cardiaca sistólica crónica, clasificación NYHA IIEUCTR2005-003351-12-ESPFIZER2,584
进行中（未招募）
不适用
The effect of eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA Class II Chronic Systolic Heart Failure - N/AChronic systolic heart failureMedDRA version: 8.0Level: LLTClassification code 10008908EUCTR2005-003351-12-SEPfizer AB2,715